Knowledge Library · Reviews

Powered by Pulse — Value Added. The #1 source of truth in revenue operations. Find the bottleneck. Fix the pipeline. Win the quarter.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x in 2027?

📖 2,832 words🗓️ Published Sep 20, 2026

Direct Answer

A fractional CRO is right for a Series A company with sub-2x pipeline coverage only when the gap is an execution or process failure, not a product-market fit problem. The fractional hire buys 90–120 days of diagnostic and hands-on selling capacity without a full-time CRO's salary and equity dilution. If coverage cannot exceed 3x within two quarters, pivot instead.

Rent this Advertising Space

Need advice or a second look at your business?From a real Chief Revenue Officer.25 years as a CRO. Tell me where it is stuck and get a straight answer on the fastest fix.Show me →Kory White · Fractional CRO →

Work with Kory Hire a Fractional CRO LinkedIn Résumé

The two options compared: fractional CRO versus full-time CRO or doing nothing

At Series A, a company with pipeline coverage below 2x faces three realistic paths, and the decision hinges on what the coverage gap actually represents. The first option is hiring a full-time CRO. The second is engaging a fractional CRO on a 90- to 120-day diagnostic and execution mandate. The third is doing nothing structural and letting the CEO keep selling while the board pressure builds. Each has a distinct cost profile, risk profile, and set of conditions under which it makes sense.

A full-time CRO at Series A typically commands a base salary in the $200,000–$300,000 range plus 1–3% equity, and the search itself takes three to six months. That means the company burns runway for a full quarter before the hire even starts, and the new CRO then needs another 60–90 days to diagnose the same pipeline problem a fractional operator would have diagnosed in the first 30 days. For a company with 12–18 months of runway and sub-2x coverage, that timeline is often fatal. The full-time CRO also carries a retention risk: if the coverage gap turns out to be a product-market fit issue rather than a sales execution issue, the company has just spent six figures and equity on a leader whose playbook cannot fix the root cause.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 1

The fractional CRO, by contrast, typically costs $15,000–$25,000 per month for three to four months, or $50,000–$100,000 total. That is roughly one to two months of a full-time CRO's fully loaded cost, and it comes with no equity grant, no long-term commitment, and no severance exposure. The fractional operator is expected to be hands-on from week one: joining sales calls, rewriting discovery scripts, auditing lost deals, and personally working the top three to five stalled opportunities. The trade-off is that a fractional CRO has less organizational authority, cannot fire and rehire the sales team unilaterally, and may be splitting attention across two or three other clients. That reduced authority is precisely why the engagement only works when the CEO and lead investor agree on a narrow, measurable mandate.

Doing nothing is the default that most companies drift into, and it is the most expensive option in disguise. When coverage sits below 2x, reps stop prospecting and start scraping the same five to seven stale opportunities. Discounting increases, forecast accuracy collapses, and the board loses confidence in management. A company that waits two more quarters before acting often finds itself raising a down round or cutting headcount instead of fixing the pipeline. The decision is therefore not "fractional versus full-time" in the abstract; it is "which option matches the actual root cause and the remaining runway."

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 2

The comparison also depends on the sales motion. A company running founder-led or inbound-led sales with a $20,000–$50,000 ACV and a 45–90 day cycle can absorb a fractional CRO who has run that exact motion before. A company that has already built a 10-person enterprise sales team with a nine-month cycle needs a full-time leader with enterprise experience, not a fractional generalist. The fractional option is strongest when the team is small (two to four reps), the motion is still being figured out, and the CEO is still the primary closer. It is weakest when the organization already has scale and simply needs a manager to run a known playbook.

How to decide between them

The decision tree below is the one a CEO and lead investor should walk through together before signing any fractional CRO agreement. It forces the conversation to start with the root cause of the sub-2x coverage, not with the desire to "hire a sales leader." The first branch is diagnostic: is the coverage gap caused by execution (reps not advancing deals, no defined process, weak discovery) or by demand and product-market fit (not enough qualified leads entering the funnel, buyers saying no to the core value proposition)? Execution problems are fixable by a fractional operator. Product-market fit problems are not.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 3

The second branch is financial: does the company have at least 12 months of runway after paying the fractional CRO's fees? If runway is under 12 months, the fractional engagement consumes $60,000–$100,000 that the company cannot afford, and the correct move is to raise a bridge or cut burn first. The third branch is the outcome test: if coverage does not exceed 3x after two quarters of fractional intervention, the problem is structural, and hiring a full-time CRO would only repeat the same failure with a bigger price tag.

A critical nuance in this decision is that the fractional CRO must be evaluated on diagnostic capability, not just selling capability. The best fractional operators will tell a CEO within 30 days whether the coverage gap is fixable. If the operator cannot articulate a clear hypothesis about the root cause after reviewing the pipeline, the lost deals, and sitting in on five sales calls, that is itself a signal that the engagement will not produce a decision. The CEO should insist on a written 30-day diagnostic memo as a contractual deliverable, not just a verbal readout.

Concrete numbers behind each option

The numbers matter because Series A companies operate on thin margins and short runways, and the wrong choice can consume a quarter of cash with no pipeline improvement. The table below lays out the realistic cost and timeline profile for each option, based on typical B2B SaaS Series A economics.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 4

Dimension	Fractional CRO	Full-time CRO	Do nothing
Monthly cost	$15,000–$25,000	$17,000–$25,000 base plus benefits and equity	$0 direct, high indirect
Total 90-day cost	$50,000–$100,000	$60,000–$90,000 plus search fees and equity	Lost quarter of ARR growth
Time to start	1–3 weeks	3–6 months search plus notice period	Immediate but no action
Equity dilution	None	1–3%	None
Diagnostic speed	30 days	60–90 days after start	Never
Hands-on selling	50–70% of time in first 60 days	10–20% of time	CEO only
Authority to fire reps	Advisory only	Full	N/A
Best fit	Execution gap, 2–4 reps, founder-led motion	Proven playbook, 5+ reps, scale motion	Never a real strategy

The fractional option's total cost of $50,000–$100,000 over three to four months is roughly equivalent to one to two months of a full-time CRO's fully loaded compensation, but it delivers a diagnostic answer in 30 days instead of 90. For a company with $500,000–$2 million in ARR and 12–18 months of runway, that speed is the entire value proposition. The company is not buying a permanent leader; it is buying a fast, objective answer to the question "is this fixable?"

The pipeline math behind the decision is equally concrete. If a company has a $300,000 quarterly target and coverage of 1.8x, it has $540,000 of pipeline. To reach 3x coverage, it needs $900,000, which means adding $360,000 of qualified pipeline in the quarter. At a $30,000 ACV, that is 12 new qualified opportunities. If the company's inbound engine generates four qualified opportunities per month and outbound generates two, the gap is real and structural. A fractional CRO who can personally source three to five opportunities per month through their own network and coaching can close part of that gap, but only if the conversion rate on existing pipeline is also fixed. If the conversion rate is broken, adding pipeline just fills a leaky bucket.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 5

The cost of a full-time CRO also includes opportunity cost. A six-month search means the company operates for two quarters without a dedicated sales leader, during which the CEO is distracted from product and fundraising. If the company raises a Series B during that period, the new CRO inherits a pipeline that has not improved, and the board's patience is already thin. The fractional model avoids that trap by keeping the CEO in the sales seat while adding diagnostic and coaching capacity alongside them.

Implementation details and sequencing

The sequencing of a fractional CRO engagement matters as much as the decision to hire one. The first 30 days are diagnostic and triage. The fractional CRO reviews every open opportunity with the CEO and each rep, categorizes the last 10 lost deals, and personally takes over the two largest stalled deals to understand the buyer's objections firsthand. They produce a three-page sales process document defining stages from lead to closed-won with exit criteria for each stage. They also reclassify the forecast, moving deals from commit to best case or upside, which will make the pipeline look worse before it looks better.

Days 31–60 are pipeline generation and rep coaching. The fractional CRO runs a 14-day pipeline blitz where the CEO, reps, and sometimes product team make 50 outbound calls per day into the ICP. They hold weekly one-on-one coaching sessions with each rep focused on discovery questions and objection handling. They also force the CEO to step back from day-to-day sales operations within 30 days; if the CEO remains the primary closer, the fractional engagement cannot succeed because the reps never develop ownership of the pipeline.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 6

Days 61–90 are system building and board communication. The fractional CRO implements a weekly pipeline review cadence, ensures the CRM (typically HubSpot or Salesforce) reflects reality, and presents a 90-day report to the board answering three questions: is the pipeline problem fixable with the current product, team, and pricing? If yes, what is the timeline to 3x coverage? If no, what is the recommendation—pivot, raise more, or shut down?

The operating cadence for the fractional CRO is three to four days per week on-site or remote with daily standups. They attend the CEO's weekly staff meeting, the weekly sales team meeting, and the monthly board meeting. They own the sales process, pipeline review, and rep coaching, but they advise only on pricing, product roadmap priorities, and customer success handoffs. The engagement should have a written scope that excludes non-sales activities; if the fractional CRO spends more than 50% of their time on customer success, product feedback, or fundraising support, the company should hire a full-time head of customer success or product manager instead.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 7

The signals to convert the fractional CRO to full-time are specific: pipeline coverage reaches 3x for two consecutive quarters, the sales team has at least three reps who can independently close deals, and the company has raised additional capital providing 18+ months of runway. The signals not to convert are equally specific: coverage remains below 2x after 90 days, the fractional CRO identifies a product-market fit issue requiring a pivot, or the fractional CRO and CEO have fundamentally incompatible operating styles. In the last case, the fractional CRO should be honest with the CEO by day 60 and help recruit a different full-time leader who matches the CEO's style.

FAQ

How much does a fractional CRO cost at Series A? Typical pricing is $15,000–$25,000 per month for a three- to four-month engagement, totaling $50,000–$100,000. There is no equity grant and no long-term commitment. This is roughly one to two months of a full-time CRO's fully loaded cost, which is why it fits a Series A operating budget.

What is the first thing a fractional CRO should do? Audit the pipeline, review every open opportunity with the CEO and each rep, categorize the last 10 lost deals, and personally take over the two largest stalled deals. The 30-day diagnostic memo identifying the root cause of sub-2x coverage is the first contractual deliverable.

How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 9

Should the CEO stay involved in sales during the engagement? The CEO should step back from day-to-day closing within 30 days. If the CEO remains the primary closer, reps never develop pipeline ownership and the fractional engagement cannot fix the coverage gap. The CEO should stay in executive sponsorship and top-deal support only.

What if the fractional CRO and CEO have different operating styles? The fractional CRO should be honest by day 60 about whether a full-time role would work. If the operator is data-driven and the CEO is intuitive, a full-time relationship will be conflict-ridden. The fractional CRO should help recruit a different full-time leader who matches the CEO's style.

Does a fractional CRO replace the need for a VP of Sales? No. A fractional CRO is a diagnostic and hands-on operator for 90–120 days. If the company converts to full-time, the fractional CRO may become the full-time CRO, or the company may hire a VP of Sales under a full-time CRO. The fractional engagement is a bridge, not a permanent org design.

How does pipeline coverage below 2x affect forecast accuracy? Severely. In a 3x coverage environment, a deal at 80% probability is genuinely likely to close. In a 1.8x environment, the same deal might be at 40% probability because the rep has no other options and is inflating the forecast. The fractional CRO must reset the forecast by reclassifying deals downward.

Sources

flowchart TD A["Pipeline coverage below 2x at Series A"] --> B{"Audit last 10 lost deals"} B --> C{"More than 50% lost to no decision or budget?"} C -- Yes --> D["Likely product-market fit or pricing issue"] D --> E["Do not hire fractional CRO yet"] E --> F["Run customer discovery, revisit ICP and pricing"] C -- No --> G["Likely execution or process issue"] G --> H{"Runway 12+ months?"} H -- No --> I["Raise bridge or cut burn first"] H -- Yes --> J["Engage fractional CRO on 90-120 day mandate"] J --> K{"Coverage above 3x after two quarters?"} K -- Yes --> L["Convert to full-time CRO or promote internally"] K -- No --> M["Pivot GTM or product, do not hire full-time CRO"]

flowchart LR A["Days 1-30: Diagnostic and triage"] --> B["Audit pipeline and lost deals"] A --> C["Take over top 2 stalled deals"] A --> D["Write 3-page sales process doc"] B --> E["Days 31-60: Pipeline generation and coaching"] C --> E D --> E E --> F["14-day outbound blitz, 50 calls per day"] E --> G["Weekly 1-on-1 rep coaching"] E --> H["CEO steps back from closing"] F --> I["Days 61-90: System building and board report"] G --> I H --> I I --> J["Weekly pipeline review cadence"] I --> K["CRM hygiene and forecast reset"] I --> L["90-day board recommendation"]

Related on PULSE

How to diagnose whether a pipeline gap is a demand problem or a conversion problem
When to hire a full-time CRO versus a fractional revenue leader
Building a 90-day sales diagnostic for Series A companies
Pipeline coverage benchmarks by ACV and sales cycle length
How RevOps supports fractional revenue leadership engagements
Signals that a Series A company should pivot go-to-market instead of hiring sales leadership

Download:

## Direct Answer

A fractional CRO is right for a Series A company with sub-2x pipeline coverage only when the gap is an execution or process failure, not a product-market fit problem. The fractional hire buys 90–120 days of diagnostic and hands-on selling capacity without a full-time CRO's salary and equity dilution. If coverage cannot exceed 3x within two quarters, pivot instead.

## The two options compared: fractional CRO versus full-time CRO or doing nothing

At Series A, a company with pipeline coverage below 2x faces three realistic paths, and the decision hinges on what the coverage gap actually represents. The first option is hiring a full-time CRO. The second is engaging a fractional CRO on a 90- to 120-day diagnostic and execution mandate. The third is doing nothing structural and letting the CEO keep selling while the board pressure builds. Each has a distinct cost profile, risk profile, and set of conditions under which it makes sense.

A full-time CRO at Series A typically commands a base salary in the $200,000–$300,000 range plus 1–3% equity, and the search itself takes three to six months. That means the company burns runway for a full quarter before the hire even starts, and the new CRO then needs another 60–90 days to diagnose the same pipeline problem a fractional operator would have diagnosed in the first 30 days. For a company with 12–18 months of runway and sub-2x coverage, that timeline is often fatal. The full-time CRO also carries a retention risk: if the coverage gap turns out to be a product-market fit issue rather than a sales execution issue, the company has just spent six figures and equity on a leader whose playbook cannot fix the root cause.

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 1](/assets/qa/q10558-b1.jpg)




















The fractional CRO, by contrast, typically costs $15,000–$25,000 per month for three to four months, or $50,000–$100,000 total. That is roughly one to two months of a full-time CRO's fully loaded cost, and it comes with no equity grant, no long-term commitment, and no severance exposure. The fractional operator is expected to be hands-on from week one: joining sales calls, rewriting discovery scripts, auditing lost deals, and personally working the top three to five stalled opportunities. The trade-off is that a fractional CRO has less organizational authority, cannot fire and rehire the sales team unilaterally, and may be splitting attention across two or three other clients. That reduced authority is precisely why the engagement only works when the CEO and lead investor agree on a narrow, measurable mandate.

Doing nothing is the default that most companies drift into, and it is the most expensive option in disguise. When coverage sits below 2x, reps stop prospecting and start scraping the same five to seven stale opportunities. Discounting increases, forecast accuracy collapses, and the board loses confidence in management. A company that waits two more quarters before acting often finds itself raising a down round or cutting headcount instead of fixing the pipeline. The decision is therefore not "fractional versus full-time" in the abstract; it is "which option matches the actual root cause and the remaining runway."

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 2](/assets/qa/q10558-b2.jpg)




















The comparison also depends on the sales motion. A company running founder-led or inbound-led sales with a $20,000–$50,000 ACV and a 45–90 day cycle can absorb a fractional CRO who has run that exact motion before. A company that has already built a 10-person enterprise sales team with a nine-month cycle needs a full-time leader with enterprise experience, not a fractional generalist. The fractional option is strongest when the team is small (two to four reps), the motion is still being figured out, and the CEO is still the primary closer. It is weakest when the organization already has scale and simply needs a manager to run a known playbook.

## How to decide between them

The decision tree below is the one a CEO and lead investor should walk through together before signing any fractional CRO agreement. It forces the conversation to start with the root cause of the sub-2x coverage, not with the desire to "hire a sales leader." The first branch is diagnostic: is the coverage gap caused by execution (reps not advancing deals, no defined process, weak discovery) or by demand and product-market fit (not enough qualified leads entering the funnel, buyers saying no to the core value proposition)? Execution problems are fixable by a fractional operator. Product-market fit problems are not.

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 3](/assets/qa/q10558-b3.jpg)




















```mermaid
flowchart TD
  A["Pipeline coverage below 2x at Series A"] --> B{"Audit last 10 lost deals"}
  B --> C{"More than 50% lost to no decision or budget?"}
  C -- Yes --> D["Likely product-market fit or pricing issue"]
  D --> E["Do not hire fractional CRO yet"]
  E --> F["Run customer discovery, revisit ICP and pricing"]
  C -- No --> G["Likely execution or process issue"]
  G --> H{"Runway 12+ months?"}
  H -- No --> I["Raise bridge or cut burn first"]
  H -- Yes --> J["Engage fractional CRO on 90-120 day mandate"]
  J --> K{"Coverage above 3x after two quarters?"}
  K -- Yes --> L["Convert to full-time CRO or promote internally"]
  K -- No --> M["Pivot GTM or product, do not hire full-time CRO"]
```

The second branch is financial: does the company have at least 12 months of runway after paying the fractional CRO's fees? If runway is under 12 months, the fractional engagement consumes $60,000–$100,000 that the company cannot afford, and the correct move is to raise a bridge or cut burn first. The third branch is the outcome test: if coverage does not exceed 3x after two quarters of fractional intervention, the problem is structural, and hiring a full-time CRO would only repeat the same failure with a bigger price tag.

A critical nuance in this decision is that the fractional CRO must be evaluated on diagnostic capability, not just selling capability. The best fractional operators will tell a CEO within 30 days whether the coverage gap is fixable. If the operator cannot articulate a clear hypothesis about the root cause after reviewing the pipeline, the lost deals, and sitting in on five sales calls, that is itself a signal that the engagement will not produce a decision. The CEO should insist on a written 30-day diagnostic memo as a contractual deliverable, not just a verbal readout.

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 4](/assets/qa/q10558-b4.jpg)




















## Concrete numbers behind each option

The numbers matter because Series A companies operate on thin margins and short runways, and the wrong choice can consume a quarter of cash with no pipeline improvement. The table below lays out the realistic cost and timeline profile for each option, based on typical B2B SaaS Series A economics.

| Dimension | Fractional CRO | Full-time CRO | Do nothing |
|---|---|---|---|
| Monthly cost | $15,000–$25,000 | $17,000–$25,000 base plus benefits and equity | $0 direct, high indirect |
| Total 90-day cost | $50,000–$100,000 | $60,000–$90,000 plus search fees and equity | Lost quarter of ARR growth |
| Time to start | 1–3 weeks | 3–6 months search plus notice period | Immediate but no action |
| Equity dilution | None | 1–3% | None |
| Diagnostic speed | 30 days | 60–90 days after start | Never |
| Hands-on selling | 50–70% of time in first 60 days | 10–20% of time | CEO only |
| Authority to fire reps | Advisory only | Full | N/A |
| Best fit | Execution gap, 2–4 reps, founder-led motion | Proven playbook, 5+ reps, scale motion | Never a real strategy |

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 5](/assets/qa/q10558-b5.jpg)




















The fractional option's total cost of $50,000–$100,000 over three to four months is roughly equivalent to one to two months of a full-time CRO's fully loaded compensation, but it delivers a diagnostic answer in 30 days instead of 90. For a company with $500,000–$2 million in ARR and 12–18 months of runway, that speed is the entire value proposition. The company is not buying a permanent leader; it is buying a fast, objective answer to the question "is this fixable?"

The pipeline math behind the decision is equally concrete. If a company has a $300,000 quarterly target and coverage of 1.8x, it has $540,000 of pipeline. To reach 3x coverage, it needs $900,000, which means adding $360,000 of qualified pipeline in the quarter. At a $30,000 ACV, that is 12 new qualified opportunities. If the company's inbound engine generates four qualified opportunities per month and outbound generates two, the gap is real and structural. A fractional CRO who can personally source three to five opportunities per month through their own network and coaching can close part of that gap, but only if the conversion rate on existing pipeline is also fixed. If the conversion rate is broken, adding pipeline just fills a leaky bucket.

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 6](/assets/qa/q10558-b6.jpg)




















The cost of a full-time CRO also includes opportunity cost. A six-month search means the company operates for two quarters without a dedicated sales leader, during which the CEO is distracted from product and fundraising. If the company raises a Series B during that period, the new CRO inherits a pipeline that has not improved, and the board's patience is already thin. The fractional model avoids that trap by keeping the CEO in the sales seat while adding diagnostic and coaching capacity alongside them.

## Implementation details and sequencing

The sequencing of a fractional CRO engagement matters as much as the decision to hire one. The first 30 days are diagnostic and triage. The fractional CRO reviews every open opportunity with the CEO and each rep, categorizes the last 10 lost deals, and personally takes over the two largest stalled deals to understand the buyer's objections firsthand. They produce a three-page sales process document defining stages from lead to closed-won with exit criteria for each stage. They also reclassify the forecast, moving deals from commit to best case or upside, which will make the pipeline look worse before it looks better.

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 7](/assets/qa/q10558-b7.jpg)




















Days 31–60 are pipeline generation and rep coaching. The fractional CRO runs a 14-day pipeline blitz where the CEO, reps, and sometimes product team make 50 outbound calls per day into the ICP. They hold weekly one-on-one coaching sessions with each rep focused on discovery questions and objection handling. They also force the CEO to step back from day-to-day sales operations within 30 days; if the CEO remains the primary closer, the fractional engagement cannot succeed because the reps never develop ownership of the pipeline.

Days 61–90 are system building and board communication. The fractional CRO implements a weekly pipeline review cadence, ensures the CRM (typically HubSpot or Salesforce) reflects reality, and presents a 90-day report to the board answering three questions: is the pipeline problem fixable with the current product, team, and pricing? If yes, what is the timeline to 3x coverage? If no, what is the recommendation—pivot, raise more, or shut down?

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 8](/assets/qa/q10558-b8.jpg)




















```mermaid
flowchart LR
  A["Days 1-30: Diagnostic and triage"] --> B["Audit pipeline and lost deals"]
  A --> C["Take over top 2 stalled deals"]
  A --> D["Write 3-page sales process doc"]
  B --> E["Days 31-60: Pipeline generation and coaching"]
  C --> E
  D --> E
  E --> F["14-day outbound blitz, 50 calls per day"]
  E --> G["Weekly 1-on-1 rep coaching"]
  E --> H["CEO steps back from closing"]
  F --> I["Days 61-90: System building and board report"]
  G --> I
  H --> I
  I --> J["Weekly pipeline review cadence"]
  I --> K["CRM hygiene and forecast reset"]
  I --> L["90-day board recommendation"]
```

The operating cadence for the fractional CRO is three to four days per week on-site or remote with daily standups. They attend the CEO's weekly staff meeting, the weekly sales team meeting, and the monthly board meeting. They own the sales process, pipeline review, and rep coaching, but they advise only on pricing, product roadmap priorities, and customer success handoffs. The engagement should have a written scope that excludes non-sales activities; if the fractional CRO spends more than 50% of their time on customer success, product feedback, or fundraising support, the company should hire a full-time head of customer success or product manager instead.

The signals to convert the fractional CRO to full-time are specific: pipeline coverage reaches 3x for two consecutive quarters, the sales team has at least three reps who can independently close deals, and the company has raised additional capital providing 18+ months of runway. The signals not to convert are equally specific: coverage remains below 2x after 90 days, the fractional CRO identifies a product-market fit issue requiring a pivot, or the fractional CRO and CEO have fundamentally incompatible operating styles. In the last case, the fractional CRO should be honest with the CEO by day 60 and help recruit a different full-time leader who matches the CEO's style.

![How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x — figure 9](/assets/qa/q10558-b9.jpg)




















## Related questions

### How do I know if sub-2x coverage is an execution problem or a product-market fit problem?

Audit the last 10 lost deals. If more than 50% were lost to no decision or budget, the issue is likely product-market fit or pricing, and a fractional CRO cannot fix it. If more than 50% were lost to competitors or timing, it is an execution problem a fractional operator can address.

### What is the minimum runway before hiring a fractional CRO?

At least 12 months. The fractional engagement costs $50,000–$100,000 over three to four months, and the company needs remaining cash to fund the pipeline generation activities the fractional CRO will recommend, such as demand gen hires or outbound tooling. Under 12 months, raise a bridge first.

### Can a fractional CRO work remotely at Series A?

On-site at least two to three days per week for the first 60 days is strongly preferred. The operator needs to observe rep behavior in real time, sit in on discovery calls, and build trust with the CEO. After 60 days, the engagement can shift to remote with weekly on-site visits.

### What happens if coverage stays below 2x after 90 days?

The fractional CRO should present a formal board recommendation by day 90: pivot pricing, ICP, or product; raise a bridge to buy time; or shut down if unit economics are broken. Hiring a full-time CRO after a failed fractional engagement repeats the same structural failure at higher cost.

## FAQ

**How much does a fractional CRO cost at Series A?**
Typical pricing is $15,000–$25,000 per month for a three- to four-month engagement, totaling $50,000–$100,000. There is no equity grant and no long-term commitment. This is roughly one to two months of a full-time CRO's fully loaded cost, which is why it fits a Series A operating budget.

**What is the first thing a fractional CRO should do?**
Audit the pipeline, review every open opportunity with the CEO and each rep, categorize the last 10 lost deals, and personally take over the two largest stalled deals. The 30-day diagnostic memo identifying the root cause of sub-2x coverage is the first contractual deliverable.

**Should the CEO stay involved in sales during the engagement?**
The CEO should step back from day-to-day closing within 30 days. If the CEO remains the primary closer, reps never develop pipeline ownership and the fractional engagement cannot fix the coverage gap. The CEO should stay in executive sponsorship and top-deal support only.

**What if the fractional CRO and CEO have different operating styles?**
The fractional CRO should be honest by day 60 about whether a full-time role would work. If the operator is data-driven and the CEO is intuitive, a full-time relationship will be conflict-ridden. The fractional CRO should help recruit a different full-time leader who matches the CEO's style.

**Does a fractional CRO replace the need for a VP of Sales?**
No. A fractional CRO is a diagnostic and hands-on operator for 90–120 days. If the company converts to full-time, the fractional CRO may become the full-time CRO, or the company may hire a VP of Sales under a full-time CRO. The fractional engagement is a bridge, not a permanent org design.

**How does pipeline coverage below 2x affect forecast accuracy?**
Severely. In a 3x coverage environment, a deal at 80% probability is genuinely likely to close. In a 1.8x environment, the same deal might be at 40% probability because the rep has no other options and is inflating the forecast. The fractional CRO must reset the forecast by reclassifying deals downward.

## Sources

- [SaaS Capital: B2B SaaS Pipeline Coverage Benchmarks](https://www.saas-capital.com/blog-posts/)
- [OpenView Partners: SaaS Benchmarks and Pipeline Metrics](https://openviewpartners.com/blog/)
- [HubSpot: Sales Pipeline Management Guide](https://blog.hubspot.com/sales/sales-pipeline)
- [Salesforce: What Is Pipeline Coverage](https://www.salesforce.com/resources/articles/sales-pipeline/)
- [Bessemer Venture Partners: State of the Cloud](https://www.bvp.com/atlas)
- [Harvard Business Review: Why Sales Teams Miss Quota](https://hbr.org/topic/sales)
- [Gartner: B2B Sales Strategy and Pipeline Research](https://www.gartner.com/en/sales)
- [LinkedIn Sales Solutions: Pipeline Coverage Best Practices](https://business.linkedin.com/sales-solutions)

## Related on PULSE

- How to diagnose whether a pipeline gap is a demand problem or a conversion problem
- When to hire a full-time CRO versus a fractional revenue leader
- Building a 90-day sales diagnostic for Series A companies
- Pipeline coverage benchmarks by ACV and sales cycle length
- How RevOps supports fractional revenue leadership engagements
- Signals that a Series A company should pivot go-to-market instead of hiring sales leadership

Was this helpful?

LinkedIn · two-step paste

1 · Paste this first

https://pulserevops.com/knowledge/q10558

Wait for the picture and card to appear, then delete this line — the card stays.

2 · Then paste this

𝗧𝗵𝗶𝘀 𝗽𝗮𝗴𝗲 𝘄𝗿𝗼𝘁𝗲 𝗶𝘁𝘀𝗲𝗹𝗳. 𝗬𝗼𝘂 𝗰𝗮𝗻 𝗹𝗲𝗮𝗿𝗻 𝘁𝗼 𝗱𝗼 𝗶𝘁 𝘆𝗼𝘂𝗿𝘀𝗲𝗹𝗳 𝗵𝗲𝗿𝗲 👇
https://pulserevops.com/ai-class

Here I answer: How do you decide if a fractional CRO is right for a Series A company when pipeline coverage below 2x in 2027?

A fractional CRO is right for a Series A company with sub-2x pipeline coverage only when the gap is an execution or process failure, not a product-market fit…

#decideifafractionalcroisright #cro #fractionalcro

No link to this page in here — the card is the link.

Sources cited

Pulse RevOps operational practicePulse RevOps operational practice

This page will be disappearing soon.

Download the whole page as a PDF to keep — just $1.